非恶性疾病二次异基因造血干细胞移植的回顾性分析
该研究回顾性分析了152例接受二次异基因造血干细胞移植的非恶性疾病患者,采用无GVHD、无移植物失败且无需后续移植的复合终点(GRSFS)评估主要失败事件。5年OS和GRSFS分别为67.0%和52.1%,移植物失败是最常见的GRSFS失败事件(24.5%)。供者类型、HLA相容性和疾病分组与结局相关。
要点
- 二次HSCT后5年OS为67.0%,GRSFS为52.1%。
- 移植物失败是最常见的GRSFS失败事件,发生率为24.5%。
- HLA 0-1抗原错配无关BM/PBSC供者、无关脐血供者及未更换供者与较低植入率相关。
核心结论
- GRSFS可作为量化非恶性疾病二次HSCT主要失败事件临床影响的指标,并指导二次移植策略。
研究设计与样本
- 回顾性分析152例接受二次异基因造血干细胞移植的非恶性疾病患者,采用GRSFS复合终点评估结局。
主要发现
- 5年OS为67.0%,5年GRSFS为52.1%。
- 移植物失败是最常见的GRSFS失败事件,发生率为24.5%。
- 多因素分析中,使用HLA 0-1抗原错配无关BM/PBSC供者、无关脐血供者及未更换供者与较低植入率相关(p < 0.01)。
- 除预处理和HLA相容性外,疾病分组是GRSFS的独立危险因素;噬血细胞性淋巴组织细胞增多症患者结局最差(p = 0.04),遗传代谢病患者倾向于更有利结局(p = 0.06)。
- 51例死亡中44例(86.6%)归因于原发病以外的原因,且不同疾病组间存在差异。
临床怎么用
- 对于非恶性疾病需二次HSCT的患者,可参考GRSFS评估主要失败事件风险,并关注供者选择(避免HLA 0-1抗原错配无关BM/PBSC或无关脐血供者、考虑更换供者)及疾病分组对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively analysed clinical outcomes of 152 patients with non-malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end-point, graft-versus-host disease (GVHD)-free, relapse (i.e. graft failure)-free and subsequent transplant-free survival (GRSFS), to assess major failure events. The 5-year overall survival (OS) and GRSFS rates were 67.0% and 52.1%, respectively. Graft failure (GF) was the most frequent GRSFS failure event, occurring in 24.5% of patients. In multivariate analysis, use of a human leucocyte antigen 0-1 antigen mismatch unrelated bone marrow (BM)/peripheral blood stem cell (PBSC) donor, unrelated cord blood (CB) donor and no donor change were associated with lower incidence of engraftment (p < 0.01). In addition to conditioning and human leucocyte antigen (HLA) compatibility in second HSCT, disease group was identified as an independent risk factor for GRSFS. Specifically, patients with haemophagocytic lymphohistiocytosis had the poorest outcome (p = 0.04), while those with inherited metabolic diseases (IMDs) tended towards more favourable outcome (p = 0.06). Among the 51 deaths, 44 (86.6%) were attributed to causes other than the original disease, with variation across disease groups. GRSFS may be a useful metric to quantify the clinical impact of major failure events and to inform strategies for second HSCT in NMDs.
引用
- Shimomura M, Kawaguchi K, Yamamoto S, et al. Second allogeneic haematopoietic stem cell transplantation for non-malignant diseases. Br J Haematol. 2026. PMID: 42951280. doi:10.1111/bjh.70913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。